Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
KDM5B predicts temozolomide-resistant subclones in glioblastoma.
Ullrich V, Ertmer S, Baginska A, Dorsch M, Gull HH, Cima I, Berger P, Dobersalske C, Langer S, Meyer L, Dujardin P, Kebir S, Glas M, Blau T, Keyvani K, Rauschenbach L, Sure U, Roesch A, Grüner BM, Scheffler B. Ullrich V, et al. Among authors: kebir s. iScience. 2023 Dec 3;27(1):108596. doi: 10.1016/j.isci.2023.108596. eCollection 2024 Jan 19. iScience. 2023. PMID: 38174322 Free PMC article.
Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
Rauschenbach L, Wieland A, Reinartz R, Kebir S, Till A, Darkwah Oppong M, Dobersalske C, Ullrich V, Ahmad A, Jabbarli R, Pierscianek D, Fröhlich H, Simon M, Brüstle O, Sure U, Glas M, Scheffler B. Rauschenbach L, et al. Among authors: kebir s. Eur J Cancer. 2020 Nov;140:130-139. doi: 10.1016/j.ejca.2020.09.017. Epub 2020 Oct 19. Eur J Cancer. 2020. PMID: 33091717
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.
Kebir S, Ullrich V, Berger P, Dobersalske C, Langer S, Rauschenbach L, Trageser D, Till A, Lorbeer FK, Wieland A, Wilhelm-Buchstab T, Ahmad A, Fröhlich H, Cima I, Prasad S, Matschke J, Jendrossek V, Remke M, Grüner BM, Roesch A, Siveke JT, Herold-Mende C, Blau T, Keyvani K, van Landeghem FKH, Pietsch T, Felsberg J, Reifenberger G, Weller M, Sure U, Brüstle O, Simon M, Glas M, Scheffler B. Kebir S, et al. Clin Cancer Res. 2023 Jan 17;29(2):488-500. doi: 10.1158/1078-0432.CCR-22-0611. Clin Cancer Res. 2023. PMID: 36239995 Free PMC article.
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
Lazaridis L, Schäfer N, Teuber-Hanselmann S, Blau T, Schmidt T, Oster C, Weller J, Tzaridis T, Pierscianek D, Keyvani K, Kleinschnitz C, Stuschke M, Scheffler B, Deuschl C, Sure U, Herrlinger U, Kebir S, Glas M. Lazaridis L, et al. Among authors: kebir s. J Cancer Res Clin Oncol. 2020 Mar;146(3):787-792. doi: 10.1007/s00432-019-03106-8. Epub 2019 Dec 11. J Cancer Res Clin Oncol. 2020. PMID: 31828428
First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma.
Lazaridis L, Bumes E, Cäcilia Spille D, Schulz T, Heider S, Agkatsev S, Schmidt T, Blau T, Oster C, Feldheim J, Stummer W, Kessler AF, Seidel C, Grauer O, Hau P, Sure U, Keyvani K, Herrlinger U, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Breuer S, Hattingen E, Scheffler B, Kebir S, Glas M. Lazaridis L, et al. Among authors: kebir s. Neurooncol Adv. 2022 Aug 24;4(1):vdac137. doi: 10.1093/noajnl/vdac137. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36284931 Free PMC article.
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma.
Schmidt T, Agkatsev S, Feldheim J, Oster C, Blau T, Sure U, Keyvani K, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M, Lazaridis L. Schmidt T, et al. Among authors: kebir s. Neurooncol Adv. 2023 Jul 20;5(1):vdad090. doi: 10.1093/noajnl/vdad090. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37547266 Free PMC article.
Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022.
Oster C, Schmidt T, Agkatsev S, Lazaridis L, Kleinschnitz C, Sure U, Scheffler B, Kebir S, Glas M. Oster C, et al. Among authors: kebir s. Neurooncol Adv. 2023 Sep 4;5(1):vdad105. doi: 10.1093/noajnl/vdad105. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37811538 Free PMC article. Review.
77 results